|
Date
|
Title
(click to view the full text) |
|
11/17/09
|
InterMune Announces Modification to On-Going Phase 2b Study of ITMN-191 in Patients with Chronic HCV Infection
|
|
11/5/09
|
InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
|
|
11/5/09
|
InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
|
|
11/4/09
|
InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
|
|
11/3/09
|
INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227
|
|
10/29/09
|
InterMune to Present at Oppenheimer Conference
|
|
10/29/09
|
InterMune to Release Third Quarter Financial Results on November 5
|
|
10/1/09
|
InterMune to Present at JMP Securities Conference
|
|
9/29/09
|
InterMune Announces Initiation of Ritonavir-Boosted ITMN-191/RG7227 Study in HCV Patients
|
|
9/17/09
|
InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
|
|
9/14/09
|
Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting
|
|
8/19/09
|
Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
|
|
8/7/09
|
InterMune to Present at Canaccord Adams Conference
|
|
8/6/09
|
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
|
|
7/29/09
|
InterMune to Release Second Quarter Financial Results on August 6
|
|
6/3/09
|
InterMune to Present at Goldman Sachs Healthcare Conference
|
|
5/19/09
|
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
|
|
5/17/09
|
Important Data Presented on Independent Predictors of Mortality in Patients With Idiopathic Pulmonary Fibrosis
|
|
5/14/09
|
Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS
|
|
4/30/09
|
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
|
|
4/25/09
|
Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
|
|
4/24/09
|
InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
|
|
4/21/09
|
INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
|
|
4/21/09
|
InterMune to Release First Quarter Financial Results on April 30
|
|
4/20/09
|
InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
|
|
4/3/09
|
InterMune to Present at Canaccord Adams Hepatitis C Conference
|
|
3/30/09
|
InterMune to Present at Citi's 4th Annual Biotech Day
|
|
3/18/09
|
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
|
|
3/18/09
|
INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
|
|
3/13/09
|
InterMune to Present at Cowen Health Care Conference
|
|
2/26/09
|
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
|
|
2/20/09
|
InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
|
|
2/19/09
|
InterMune Announces Issuance of U.S. Patent for ITMN-191
|
|
2/13/09
|
InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
|
|
2/3/09
|
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
|
|
2/2/09
|
InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
|
|
1/12/09
|
InterMune Reports Results from Triple Combination Study of ITMN-191
|
|
1/9/09
|
InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
|
|
1/6/09
|
InterMune to Present at J.P. Morgan Healthcare Conference
|
|
12/10/08
|
InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
|
|
11/14/08
|
InterMune to Present at Lazard Capital Markets Healthcare Conference
|
|
11/10/08
|
Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
|
|
11/7/08
|
InterMune to Present at Deutsche Bank Biotech Boston Confab
|
|
11/6/08
|
InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
|
|
10/28/08
|
InterMune to Release Third Quarter 2008 Financial Results on November 6
|
|
10/16/08
|
InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
|
|
9/24/08
|
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
|
|
9/8/08
|
InterMune to Present at Baird Small Cap Healthcare Conference
|
|
9/2/08
|
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
|
|
8/29/08
|
InterMune to Present at Thomas Weisel Partners Healthcare Conference
|
|
8/7/08
|
InterMune to Present at Canaccord Adams Conference
|
|
7/31/08
|
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
|
|
7/30/08
|
InterMune to Present at BMO Healthcare Conference
|
|
7/24/08
|
InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
|
|
6/20/08
|
InterMune to Present at Jefferies Healthcare Conference
|
|
6/6/08
|
InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
|
|
5/29/08
|
InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
|
|
5/19/08
|
InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
|
|
5/16/08
|
InterMune to Present at Citigroup Healthcare Conference
|
|
5/9/08
|
InterMune to Present at Bank of America Health Care Conference
|
|
5/1/08
|
InterMune Reports First Quarter 2008 Financial Results and Business Highlights
|
|
4/30/08
|
InterMune to Present at Deutsche Bank Health Care Conference
|
|
4/24/08
|
InterMune to Release First Quarter 2008 Financial Results on May 1
|
|
4/21/08
|
InterMune Announces Progress on Pirfenidone in IPF
|
|
4/2/08
|
InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
|
|
4/1/08
|
InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
|
|
3/18/08
|
Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
|
|
3/12/08
|
InterMune to Present at Cowen and Company and Lehman Brothers Health Care Conferences
|
|
2/28/08
|
InterMune to Present at the SIGnificant Options in Healthcare Conference
|
|
2/7/08
|
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
|
|
1/24/08
|
InterMune to Release Fourth Quarter, Full Year 2007 Financial Results on February 7
|
|
1/23/08
|
InterMune to Present at the 2008 Wachovia Healthcare Conference
|
|
1/7/08
|
InterMune Announces Continuing Progress on ITMN-191 (R7227)
|
|
1/2/08
|
InterMune to Present at the 26th Annual JPMorgan Healthcare Conference
|
|
11/26/07
|
InterMune Buys Out License Agreement for Pirfenidone
|
|
11/1/07
|
InterMune Announces Third Quarter 2007 Financial Results and Business Highlights
|
|
10/31/07
|
InterMune to Present at CIBC Healthcare Conference
|
|
10/22/07
|
InterMune to Release Third Quarter 2007 Financial Results on November 1
|
|
9/26/07
|
InterMune Announces Closing of Public Offering of Common Stock
|
|
9/26/07
|
InterMune Announces Start of Phase 1b Trial of ITMN-191
|
|
9/21/07
|
InterMune Announces Pricing of $68 Million Public Offering of Common Stock
|
|
9/18/07
|
InterMune Announces Proposed Public Offering of Common Stock
|
|
9/6/07
|
Louis Drapeau Elected to InterMune Board of Directors
|
|
9/4/07
|
InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
|
|
8/30/07
|
InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
|
|
8/2/07
|
InterMune Announces Second Quarter 2007 Financial Results and Business Highlights
|
|
7/24/07
|
InterMune Submits CTA Amendment for ITMN-191 and Provides Update on Clinical Development Program
|
|
6/22/07
|
InterMune to Present at the Jefferies Healthcare Conference
|
|
6/8/07
|
InterMune to Present at the Goldman Sachs 28th Annual Global Healthcare Conference
|
|
5/21/07
|
InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
|
|
5/17/07
|
InterMune to Present at the Citigroup 2007 Healthcare Conference
|
|
5/16/07
|
InterMune Completes Patient Enrollment in Phase 3 'Capacity' Program Evaluating Pirfenidone in Patients With IPF
|
|
5/3/07
|
InterMune Announces First Quarter 2007 Financial Results and Business Highlights
|
|
4/27/07
|
InterMune to Present at the 2007 Deutsche Bank Health Care Conference
|
|
4/26/07
|
InterMune to Release First Quarter 2007 Financial Results on May 3
|
|
4/11/07
|
InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
|
|
4/4/07
|
InterMune to Present at the CIBC Biotechnology and Specialty Pharmaceuticals Conference
|
|
3/20/07
|
InterMune Updates Expense Forecasts and Development Plans
|
|
3/15/07
|
InterMune to Extend Filing Date for Annual Report on Form 10-K
|
|
3/5/07
|
InterMune Discontinues Phase 3 INSPIRE Trial of Actimmune in Idiopathic Pulmonary Fibrosis
|
|
2/23/07
|
InterMune to Present at the SIGnificant Investment Options in Healthcare Conference
|
|
2/8/07
|
InterMune Announces Fourth Quarter and Full Year 2006 Financial Results
|
|
1/25/07
|
InterMune to Release Fourth quarter, Full Year 2006 Financial Results on February 8
|
|
1/25/07
|
InterMune to Present at the Wachovia Securities 2007 Healthcare Conference
|
|
1/9/07
|
InterMune Achieves Manufacturing Milestone in HCV Collaboration With Roche
|
|
1/4/07
|
InterMune to Present at the JPMorgan Healthcare Conference
|
|
12/28/06
|
InterMune Announces Filing of Shelf Registration Statement
|
|
12/19/06
|
InterMune Initiates Phase 1a Clinical Trial Evaluating Hepatitis C Protease Inhibitor ITMN-191 in Collaboration with Roche
|
|
11/30/06
|
InterMune to Present at the BMO Capital Markets Focus on Healthcare Conference
|
|
11/8/06
|
InterMune to Present at the ThinkEquity Partners ThinkTank
|
|
11/6/06
|
InterMune to Present at the CIBC World Markets Healthcare Conference
|
|
11/2/06
|
InterMune Closes Collaboration Agreement With Roche
|
|
10/30/06
|
InterMune Presents at Two Liver Disease Conferences Research on ITMN-191 in Hepatitis C
|
|
10/26/06
|
InterMune Announces Third Quarter Financial Results and Business Highlights
|
|
10/25/06
|
InterMune to Present at the C.E. Unterberg, Towbin Life Sciences Conference
|
|
10/24/06
|
InterMune to Present Research on ITMN-191 in Hepatitis C at Two Liver Disease Conferences
|
|
10/24/06
|
InterMune Presents Preclinical Data Showing Additive Anti-Fibrotic Combination Effects of Actimmune and Pirfenidone
|
|
10/16/06
|
InterMune Announces Conference Call and Webcast to Discuss Collaboration Agreement with Roche
|
|
10/16/06
|
Roche and InterMune Sign Agreement to Collaborate on the Research, Development and Commercialization of Hepatitis C Protease Inhibitors
|
|
10/6/06
|
InterMune to Release Third Quarter 2006 Financial Results on October 26
|
|
9/26/06
|
InterMune Submits Clinical Trial Authorization Application for ITMN-191 for Hepatitis C Infections
|
|
9/21/06
|
InterMune Elects Lars Ekman, M.D., Ph.D. to Board of Directors
|
|
9/20/06
|
InterMune to Present at the UBS Global Life Sciences Conference
|
|
9/6/06
|
InterMune to Present at the Bear Stearns Healthcare Conference and the ThinkEquity Partners Growth Conference
|
|
8/31/06
|
InterMune to Present at the Thomas Weisel Partners Healthcare Conference
|
|
7/31/06
|
InterMune Appoints John C. Hodgman as Chief Financial Officer
|
|
7/27/06
|
InterMune Announces Second Quarter Financial Results
|
|
7/10/06
|
InterMune to Release Second Quarter 2006 Financial Results on July 27
|
|
6/22/06
|
InterMune to Present at the Jefferies Life Sciences Conference
|
|
6/6/06
|
InterMune to Present at the Pacific Growth Equities Conference & the Needham Biotechnology and Medical Technology Conference
|
|
5/23/06
|
InterMune Presents New Preclinical Data on Its HCV Protease Inhibitor at Digestive Disease Week
|
|
5/22/06
|
InterMune Presents Preclinical Data for Actimmune(R) and Pirfenidone at American Thoracic Society Conference
|
|
5/17/06
|
InterMune Announces HCV Protease Inhibitor Presentations at Digestive Disease Week
|
|
5/17/06
|
InterMune Announces Presentations on Actimmune(R) and Pirfenidone at American Thoracic Society Conference
|
|
5/10/06
|
InterMune to Present at the Bank of America 2006 Health Care Conference
|
|
5/8/06
|
InterMune Presents Preclinical Data Identifying a Principal Mechanism of Anti-Fibrotic Action for Pirfenidone
|
|
4/27/06
|
InterMune Announces First Quarter Financial Results and Business Highlights
|
|
4/27/06
|
InterMune Initiates Phase III Program Evaluating Pirfenidone in Patients With IPF
|
|
4/26/06
|
InterMune to Present at the Deutsche Bank 2006 Health Care Conference
|
|
4/18/06
|
InterMune Completes Enrollment of the Phase III INSPIRE Trial
|
|
4/6/06
|
InterMune to Release First Quarter 2006 Financial Results on April 27
|
|
3/16/06
|
InterMune to Present at the Bear Biotech West Coast Confab
|
|
3/2/06
|
InterMune to Present at the 5th Annual JMP Securities Research Conference
|
|
2/2/06
|
InterMune Announces Fourth Quarter and Year End 2005 Financial Results
|
|
2/2/06
|
InterMune Discontinues Ovarian Cancer Trial
|
|
1/12/06
|
InterMune to Release Fourth Quarter & Year-End 2005 Financial Results on February 2
|
|
1/5/06
|
InterMune to Present at the 24th Annual JPMorgan Healthcare Conference
|
|
1/3/06
|
InterMune Completes Divestiture of Infergen(R) for up to $135.5 Million in Cash
|
|
12/27/05
|
InterMune Announces Divestiture of Oritavancin
|
|
12/1/05
|
InterMune Elects David S. Kabakoff, Ph.D. To Board Of Directors
|
|
11/28/05
|
InterMune Sharpens Focus on Key Development Programs and Significantly Strengthens Financial Position
|
|
11/14/05
|
InterMune Announces Clinical Data Presented at AASLD That Support Phase III DIRECT Trial for HCV
|
|
11/14/05
|
InterMune Presents HCV Protease Inhibitor Data at AASLD
|
|
11/9/05
|
InterMune Enrolls 600th Patient in Phase III INSPIRE Clinical Trial
|
|
11/8/05
|
InterMune Announces Presentations at the 56th Annual Meeting of the American Association for the Study of Liver Diseases
|
|
11/1/05
|
InterMune Presents In Vitro Data at Annual Meeting of the American College of Chest Physicians
|
|
10/27/05
|
InterMune Announces Third Quarter Financial Results and Business Highlights
|
|
10/20/05
|
InterMune Announces Presentations at Annual Meeting of the American College of Chest Physicians
|
|
10/17/05
|
InterMune Provides Update on Its Two Phase III Pulmonology Programs
|
|
10/14/05
|
InterMune to Release Third Quarter Financial Results on October 27
|
|
9/21/05
|
InterMune Announces Webcast of Corporate Presentation at the UBS Global Life Sciences Conference
|
|
9/8/05
|
InterMune Announces Webcast of Corporate Presentation at the ThinkEquity Partners Growth Conference
|
|
9/7/05
|
Intermune Announces Issuance of Two Composition of Matter Patents for Actimmune(R)
|
|
7/28/05
|
InterMune Announces Second Quarter Financial Results
|
|
7/19/05
|
InterMune and Array BioPharma Expand Hepatitis C Drug Discovery Collaboration
|
|
7/12/05
|
InterMune to Release Second Quarter Financial Results on July 28
|
|
7/11/05
|
InterMune Completes Enrollment of the Phase III DIRECT Trial Evaluating Daily Infergen Plus Ribavirin in PEG-Nonresponders
|
|
6/2/05
|
InterMune Announces Webcast of Corporate Presentation at the Pacific Growth Equities Life Sciences Conference
|
|
5/24/05
|
InterMune Announces Divestiture of Amphotec
|
|
5/23/05
|
Data Presented at ATS 2005 Support Intermune's Current Phase III Trial Design Evaluating Actimmune(R) in IPF Patients
|
|
5/16/05
|
InterMune Announces Presentation of Clinical Data From Studies of Daily Infergen With and Without Ribavirin for the Treatment of HCV
|
|
5/16/05
|
InterMune Announces Presentation of Data on Infergen Plus Actimmune for the Treatment of HCV PEG-Nonresponders
|
|
5/16/05
|
InterMune Announces Presentation of Specificity and Tolerability Data for Two Novel Protease Inhibitor Drug Candidates
|
|
5/9/05
|
InterMune Reaches Preliminary Settlement Agreement for Shareholder Class Action Lawsuit
|
|
5/9/05
|
InterMune Announces Hepatitis C Presentations at Digestive Disease Week
|
|
5/9/05
|
InterMune Announces Presentations on Actimmune and IPF at ATS 2005
|
|
5/2/05
|
Promising Results From Phase II Study of Pirfenidone in IPF Patients
|
|
4/28/05
|
InterMune Announces First Quarter Financial Results
|
|
4/7/05
|
InterMune to Release First Quarter Financial Results on April 28
|
|
3/29/05
|
InterMune Provides an Update on Pirfenidone Development Plans
|
|
3/9/05
|
InterMune Announces Webcast of Corporate Presentation at the SG Cowen & Co. 25th Annual Health Care Conference
|
|
2/23/05
|
Intermune Announces Webcast of Corporate Presentation at the Wells Fargo 2005 Healthcare Conference
|
|
2/23/05
|
InterMune Announces Webcast of Corporate Presentation at the JMP Securities 4th Annual Research Conference
|
|
2/18/05
|
InterMune Announces Management Appointment
|
|
2/7/05
|
InterMune Announces Fourth Quarter and Year End Financial Results
|
|
1/25/05
|
InterMune to Release Fourth Quarter and Year-End 2004 Financial Results on February 7
|
|
1/10/05
|
InterMune Announces Webcast of Corporate Presentation at the JPMorgan Healthcare Conference
|
|
1/10/05
|
Largest Completed IPF Study Points to Survival as Key Endpoint in Future Actimmune Studies
|
|
12/2/04
|
InterMune Announces Webcast of Corporate Presentation at the Harris Nesbitt Healthcare Conference
|
|
11/9/04
|
InterMune Receives Subpoena from the Department of Justice
|
|
11/4/04
|
InterMune Announces Senior Management Appointment
|
|
11/2/04
|
InterMune Announces Presentation of Clinical Data on Infergen Plus Ribavirin in Difficult to Treat HCV Patients
|
|
11/1/04
|
InterMune Announces Presentation of Data on Potent HCV Protease Inhibitor Drug Candidates
|
|
11/1/04
|
InterMune Announces Presentation of Interim Clinical Data on the Combination of Daily Infergen Plus Actimmune in HCV PEG-Nonresponders
|
|
11/1/04
|
InterMune Announces Amendment of Agreement With Warburg Pincus
|
|
10/28/04
|
InterMune Announces Presentation of IPF Data at the 70th Annual Meeting of the American College of Chest Physicians
|
|
10/27/04
|
InterMune Announces Third Quarter Financial Results
|
|
10/25/04
|
InterMune Announces Presentations at the 55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
|
|
10/25/04
|
InterMune Announces Appointment of CFO
|
|
10/20/04
|
InterMune Announces Abstracts to Be Presented at The 70th Annual Meeting of the American College of Chest Physicians
|
|
10/14/04
|
InterMune to Release Third Quarter Financial Results on October 27
|
|
9/22/04
|
InterMune Announces Webcast of Corporate Presentation at the UBS Global Life Sciences Conference
|
|
9/13/04
|
InterMune Signs Agreement with Chiron Corporation to License Access to Hepatitis C Genome
|
|
9/9/04
|
InterMune Announces Resale Registration Statement Declared Effective by SEC
|
|
9/9/04
|
InterMune Announces Webcast of Corporate Presentation at the Bear Stearns 17th Annual Healthcare Conference
|
|
8/17/04
|
InterMune Announces Executive Management Changes
|
|
7/29/04
|
InterMune Announces Second Quarter Financial Results
|
|
7/28/04
|
InterMune Announces Webcast of Corporate Presentation at Adams Harkness' 24th Annual Summer Seminar
|
|
7/21/04
|
InterMune to Release Second Quarter Financial Results on July 29
|
|
7/15/04
|
InterMune Announces Completion of Repurchase of 5.75 Percent Convertible Subordinated Notes
|
|
6/15/04
|
InterMune Initiates First Pivotal Phase III Trial of Daily Infergen Plus Ribavirin for the Treatment of Hepatitis C Nonresponders
|
|
6/2/04
|
InterMune Announces Results of Annual Meeting of Stockholders
|
|
5/17/04
|
InterMune Announces Presentation of Clinical Data on the Combination of Infergen Plus Actimmune in Hepatitis C Nonresponders
|
|
5/17/04
|
InterMune Announces Presentation of Positive Results From Two Investigator-Sponsored Trials of Daily Infergen Plus Ribavirin Combination Therapy in Hepatitis C Nonresponders
|
|
5/14/04
|
InterMune Announces Webcast of Corporate Presentation at the Banc of America Securities Healthcare Conference
|
|
5/13/04
|
InterMune Initiates Phase II Clinical Trial of Daily Infergen Plus Actimmune for the Treatment of Hepatitis C Nonresponders
|
|
5/12/04
|
InterMune Announces Presentations at Digestive Disease Week
|
|
4/29/04
|
InterMune Announces First Quarter Financial Results
|
|
4/20/04
|
InterMune to Release First Quarter Financial Results on April 29
|
|
4/15/04
|
InterMune Announces Early Completion of Enrollment of Pivotal Phase III Trial of Actimmune Plus Standard Therapy for Advanced Ovarian Cancer
|
|
3/31/04
|
InterMune Charts New Course for Future
|
|
3/30/04
|
InterMune Announces Publication of Study Analyzing the Biological Effects of Interferon Gamma-1b (Actimmune(R)) in Idiopathic Pulmonary Fibrosis
|
|
3/29/04
|
Baxter and InterMune Sign Agreement for the Co-Promotion of ARALAST in the Pulmonology Arena
|
|
3/24/04
|
InterMune's Pirfenidone Granted U.S. Orphan Drug Designation for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
|
|
3/22/04
|
InterMune to Hold Analyst Day on March 31st to Provide Overview of New Strategic Course and Opportunities for the Future
|
|
2/19/04
|
InterMune Announces Webcast of Corporate Presentation at the 6th Annual BIO CEO & Investor Conference
|
|
2/11/04
|
InterMune to Issue $150 Million Principal Amount of Convertible Notes in Private Offering
|
|
2/9/04
|
InterMune Announces Proposed Convertible Debt Offering
|
|
2/4/04
|
InterMune Initiates Limited Early Access Program for Pirfenidone for Idiopathic Pulmonary Fibrosis
|
|
1/29/04
|
InterMune Announces Fourth Quarter and Year End Financial Results
|
|
1/22/04
|
InterMune Announces Departure of James Pennington, M.D.
|
|
1/21/04
|
InterMune Announces Results of Exploratory Phase II Study Of Interferon Gamma-1b in Advanced Liver Fibrosis
|
|
1/20/04
|
InterMune Appoints Michael L. Smith to Board of Directors
|
|
1/16/04
|
InterMune to Release Fourth Quarter and Year-End 2003 Financial Results on January 29
|
|
1/7/04
|
InterMune Announces New England Journal of Medicine Publication of Phase III Study of Actimmune for Idiopathic Pulmonary Fibrosis
|
|
1/7/04
|
InterMune Announces Webcast of Corporate Presentation At the 22nd Annual JPMorgan Healthcare Conference
|
|
12/16/03
|
InterMune Announces Presentation of Interim Findings of the First Clinical Experience of Infergen Plus Actimmune Combination Therapy in Hepatitis C Nonresponders
|
|
12/16/03
|
InterMune Initiates Pivotal Phase III Clinical Trial of Actimmune For Idiopathic Pulmonary Fibrosis
|
|
12/5/03
|
InterMune Announces Webcast of Corporate Presentation at the Harris Nesbitt Gerard Healthcare Investor Conference
|
|
11/21/03
|
InterMune Updates Timing of Oritavancin NDA Submission
|
|
10/30/03
|
InterMune Announces Third Quarter Financial Results
|
|
10/29/03
|
InterMune Announces the Presentation of Positive Results From Investigator-Sponsored Trial of Infergen/Ribavirin Combination Therapy in Treatment of Hepatitis C Nonresponders
|
|
10/24/03
|
InterMune Announces Abstracts to Be Presented at the 2003 Meeting of the American College of Chest Physicians
|
|
10/22/03
|
InterMune Announces Abstracts to be Presented at the 54th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
|
|
10/17/03
|
InterMune to Announce Third Quarter 2003 Financial Results on October 30
|
|
9/25/03
|
InterMune Announces Executive Management Changes
|
|
9/19/03
|
InterMune Announces Webcast of Corporate Presentation at UBS Warburg Global Life Sciences Conference
|
|
9/15/03
|
InterMune Presents Oritavancin Data at 43rd Interscience Conference On Antimicrobial Agents and Chemotherapy
|
|
9/11/03
|
InterMune Announces Abstracts to Be Presented at Interscience Conference On Antimicrobial Agents and Chemotherapy (ICAAC)
|
|
9/5/03
|
InterMune and Joseph L. Stendig Announce Settlement of Lawsuit
|
|
9/5/03
|
InterMune Announces Webcast of Corporate Presentation at Bear Stearns Healthcare Conference
|
|
8/5/03
|
InterMune Announces Webcast of Corporate Presentation At Adams, Harkness & Hill Summer Seminar
|
|
7/29/03
|
InterMune Announces Second Quarter Financial Results
|
|
7/17/03
|
InterMune to Release Second Quarter 2003 Financial Results on July 29
|
|
7/10/03
|
InterMune Appoints Executive Vice President of Commercial Operations
|
|
6/30/03
|
InterMune Announces Executive Management Change
|
|
6/23/03
|
InterMune Announces Webcast of Corporate Presentation at the 13th Annual Wachovia Securities Nantucket Equity Conference
|
|
6/11/03
|
Intermune Announces Positive Top-Line Phase III Clinical Trial Results Of Oritavancin Antibiotic For Bacterial Skin Infections
|
|
6/11/03
|
Intermune Provides Updated 2003 Financial Guidance
|
|
5/19/03
|
InterMune Announces Interim Data Showing High Early Virologic Response To Infergen in Peg-Interferon Non-Responders With Chronic Hepatitis C
|
|
5/19/03
|
Intermune Announces Results of Actimmune Biomarker Study In Idiopathic Pulmonary Fibrosis
|
|
5/19/03
|
InterMune Announces Favorable New Clinical Results of Actimmune(R) In Idiopathic Pulmonary Fibrosis
|
|
5/14/03
|
InterMune Announces Promising Clinical Results With Actimmune for IPF To Be Presented at ATS Meeting Next Week
|
|
5/13/03
|
InterMune Announces Executive Appointments and Promotion
|
|
5/12/03
|
InterMune Announces Potent Antibiotic Activity of Oritavancin In In Vitro Studies Presented at ECCMID
|
|
5/9/03
|
InterMune Announces Results From Phase II Trial of Pirfenidone for Pulmonary Fibrosis
|
|
4/29/03
|
InterMune Announces First Quarter Financial Results
|
|
4/16/03
|
InterMune to Release First Quarter 2003 Financial Results on April 29
|
|
4/9/03
|
InterMune to Announce Phase II Results Evaluating Mechanisms of Action of Actimmune in IPF
|
|
3/31/03
|
InterMune Provides Update on Applied Research Programs in Hepatitis C At Cytokine Meeting
|
|
3/24/03
|
InterMune Announces Webcast of Corporate Presentation at Banc of America Securities Healthcare Conference
|
|
3/4/03
|
Surromed Announces Biomarker Discovery Agreement With InterMune
|
|
2/25/03
|
InterMune Announces Webcast of Corporate Presentation at Lehman Brothers 6th Annual Global Healthcare Conference
|
|
2/19/03
|
InterMune Announces Fourth Quarter and Year End Financial Results
|
|
2/4/03
|
InterMune Provides Update on IPF Development Programs at Merrill Lynch Conference
|
|
2/3/03
|
InterMune Names Thomas R. Hodgson to Board of Directors
|
|
1/30/03
|
InterMune Announces Senior Management Change
|
|
1/29/03
|
InterMune Announces Webcast of Corporate Presentation at Merrill Lynch Global Pharmaceutical Biotechnology and Medical Device Conference
|
|
1/23/03
|
InterMune Initiates Phase I Study of PEG-Alfacon for the Treatment of Chronic Hepatitis C Infections
|
|
1/21/03
|
InterMune to Release Fourth Quarter 2002 Financial Results on February 19
|
|
1/6/03
|
InterMune to Update Investors at the 21st Annual JP Morgan H&Q Healthcare Conference
|
|
1/2/03
|
InterMune Announces Webcast of Corporate Presentation at JPMorgan 21st Annual Healthcare Conference
|
|
11/21/02
|
InterMune Promotes Dr. Brian Murphy to Vice President of Marketing And Commercial Strategy, Hepatology
|
|
11/12/02
|
Intermune Announces Webcast of Corporate Presentation at Credit Suisse First Boston Health Care Conference
|
|
11/5/02
|
InterMune Announces Phase IV Study Shows Infergen Combination Therapy More Effective Than Rebetron for Hepatitis C
|
|
10/31/02
|
Intermune Announces Actimmune Data to Be Presented at Annual CHEST Meeting Next Week
|
|
10/30/02
|
Intermune Announces Five Infergen Abstracts to Be Presented at Annual Liver Disease Meeting Next Week
|
|
10/24/02
|
InterMune Announces Third Quarter Financial Results
|
|
10/24/02
|
Intermune Completes Enrollment for Second Phase III Trial of Oritavancin For Bacterial Skin Infections
|
|
10/23/02
|
InterMune Completes Patient Randomization of Phase II Trial of Actimmune For Treatment of Liver Fibrosis
|
|
10/23/02
|
InterMune Announces Webcast of Corporate Presentation At Salomon Smith Barney 2002 Health Care Conference
|
|
10/15/02
|
InterMune to Release Third Quarter 2002 Financial Results on October 24
|
|
10/8/02
|
InterMune and Inhale Announce Agreement to Develop PEGylated Infergen For Hepatitis C Infections
|
|
10/4/02
|
InterMune Appoints Randall E. Kaye, M.D. Vice President of Medical Affairs
|
|
10/2/02
|
InterMune Announces Webcast of Corporate Presentation at UBS Warburg Global Life Sciences Conference
|
|
9/30/02
|
InterMune Announces Lilly Exercises Option to Buy Down Oritavancin Royalty Payments
|
|
9/30/02
|
InterMune and Array BioPharma Announce Drug Discovery Collaboration Focused on Hepatitis
|
|
9/19/02
|
InterMune Appoints Sharon Surrey-Barbari Senior Vice President and Chief Financial Officer
|
|
9/18/02
|
New IPF Therapies Highlighted at European Respiratory Society Annual Congress in Stockholm
|
|
9/12/02
|
InterMune Announces Webcast of Corporate Presentation at Bear Stearns 15th Annual Healthcare Conference
|
|
7/18/02
|
InterMune Announces Second Quarter Financial Results and Increases 2002 Revenue Forecast
|
|
7/17/02
|
InterMune Appoints Keith A. Katkin, Vice President, Pulmonary Marketing
|
|
7/11/02
|
InterMune Elects William R. Ringo, Jr. and William A. Halter To Board of Directors
|
|
7/10/02
|
InterMune to Host Corporate and Product Development Update
|
|
7/1/02
|
InterMune to Release Second Quarter 2002 Financial Results on July 18
|
|
5/30/02
|
InterMune Appoints Renowned Researchers to Lead Company's Hepatitis Research And Development Programs
|
|
5/22/02
|
InterMune Announces Long-Term Follow Up Data From Phase II Study of Actimmune In IPF Demonstrates Survival Benefit
|
|
5/16/02
|
InterMune Announces That Data at American Thoracic Society Annual Meeting Next Week Will Highlight Anti-Fibrotic Pipeline
|
|
5/14/02
|
InterMune Acquires Interferon Gamma-1b Patent Estate From Amgen
|
|
5/8/02
|
InterMune Announces Senior Management Changes
|
|
5/6/02
|
InterMune Appoints Marianne Armstrong, Ph.D., Senior Vice president, Global Regulatory Operations and Corporate Compliance
|
|
4/30/02
|
InterMune Appoints Edgar G. Engleman, M.D., Chairman, Scientific Advisory Board
|
|
4/24/02
|
InterMune Announces First Quarter Financial Results
|
|
4/19/02
|
InterMune to Release First Quarter 2002 Earnings on Wednesday, April 24, 2002
|
|
4/10/02
|
InterMune and Mondobiotech Form R&D Alliance for Actimmune(R) in Pulmonary Diseases
|
|
4/8/02
|
InterMune Licenses Promising Oral Drug to Expand Anti-Fibrotic Franchise
|
|
3/27/02
|
InterMune to Present at the Banc of America Securities Healthcare Conference
|
|
3/7/02
|
InterMune Prices Public Offering of 3,000,000 Shares of Common Stock
|
|
2/28/02
|
InterMune Announces Proposed Public Offering of Common Stock
|
|
2/25/02
|
InterMune Announces Audiocast of Presentation at Lehman Brothers Global Healthcare Conference
|
|
2/19/02
|
InterMune Announces Webcast of Presentation at BIO CEO And Investor Conference 2002
|
|
2/13/02
|
InterMune Announces Fourth Quarter and Year-End Financial Results
|
|
2/7/02
|
InterMune to Hold Conference Call to Discuss Fourth Quarter and Year End Financial Results
|
|
2/5/02
|
InterMune Announces Start of Phase III Clinical Trial Of Actimmune for the Treatment of Ovarian Cancer
|
|
1/31/02
|
InterMune Promotes David A. Cory, R.Ph. to Senior Vice President of Sales And Marketing to Lead Expanded Sales Force
|
|
1/31/02
|
InterMune Relaunches Infergen for Hepatitis C Infections
|
|
1/16/02
|
InterMune Announces Phase III IPF Study Status
|
|
1/15/02
|
InterMune Announces Webcast of Presentation at Wachovia Securities Integrated Oncology Conference
|
|
1/10/02
|
InterMune Announces Agreement With Abbott for the Manufacture of Oritavancin
|
|
1/8/02
|
InterMune Announces Start of Phase II Trial of Actimmune for the Treatment Of Liver Fibrosis
|
|
1/7/02
|
InterMune Announces Webcast of Presentation at 20th Annual JPMorgan H&Q Healthcare Conference
|
|
1/7/02
|
InterMune Receives Fast Track Designation From FDA for Actimmune In the Treatment of Idiopathic Pulmonary Fibrosis
|
|
12/21/01
|
InterMune Announces Filing of Shelf Registration Statement
|
|
12/17/01
|
InterMune Announces Positive Phase II Results of Actimmune(R) For the Treatment of Cryptococcal Meningitis
|
|
12/17/01
|
InterMune Announces Positive Phase III Clinical Trial Results for Oritavancin In Bacterial Skin Infections
|
|
12/13/01
|
InterMune Announces Five Abstracts to Be Presented at ICAAC Annual Meeting Highlighting Infectious Disease Pipeline
|
|
11/26/01
|
InterMune Announces Strategy for Future Growth Fueled by Product Sales And Clinical Development Momentum
|
|
11/12/01
|
Intermune Announces Positive Clinical Data Using Infergen(R) For the Treatment of Hepatitis C
|
|
11/9/01
|
Intermune Announces Four Infergen(R) Abstracts to Be Presented at Annual Liver Disease Meeting
|
|
10/30/01
|
InterMune Announces Webcast of Presentation at Salomon Smith Barney Health Care Conference 2001
|
|
10/24/01
|
InterMune Announces Third Quarter 2001 Financial Results
|
|
10/16/01
|
InterMune Expands International Strategic Partnership With Boehringer Ingelheim to Include Ovarian Cancer
|
|
10/11/01
|
InterMune Conference Call to Discuss Third-Quarter Financial Results Scheduled for Wednesday, October 24, 2001
|
|
10/9/01
|
InterMune to Present at UBS Warburg Global Life Sciences Conference
|
|
9/20/01
|
InterMune Announces Conference Call to Discuss Acquisition of Oritavancin Antibiotic From Lilly
|
|
9/20/01
|
Lilly Licenses Oritavancin Antibiotic to InterMune
|
|
9/19/01
|
InterMune Receives FDA Approval for Transfer of Actimmune(R) Manufacture To Boehringer Ingelheim
|
|
9/5/01
|
InterMune and Maxygen Form Collaboration to Develop Next-Generation Interferon Gamma Products
|
|
8/27/01
|
InterMune Announces Key Executive Appointments to Fuel Global Pipeline Development
|
|
8/21/01
|
InterMune Completes Target Enrollment for Phase III Trial of Actimmune for The Treatment of Idiopathic Pulmonary Fibrosis
|
|
8/16/01
|
InterMune to Develop Compound for the Treatment and Prevention of Pseudomonas Infections
|
|
8/14/01
|
InterMune Announces Executive Appointments
|
|
8/1/01
|
InterMune Announces Webcast of Presentation at Adams, Harkness & Hill's 21st Annual Summer Seminar
|
|
7/26/01
|
InterMune Announces Second Quarter 2001 Financial Results and Conference Call
|
|
7/18/01
|
InterMune Adopts Stockholder Rights Plan
|
|
7/16/01
|
InterMune Conference Call to Discuss Second Quarter Financial Results Scheduled for Thursday, July 26, 2001
|
|
7/6/01
|
Intermune Closes Public Offerings of $287 Million of Common Stock And Convertible Notes
|
|
6/29/01
|
InterMune Prices Public Offering of $250,000,000 of Common Stock And Convertible Notes
|
|
6/15/01
|
Intermune Announces Updated 2001 Financial Guidance and Conference Call
|
|
6/15/01
|
InterMune Amends Registration Statement to Add Concurrent Offering Of $125 Million of Convertible Subordinated Notes
|
|
6/15/01
|
InterMune Licenses Infergen(R) From Amgen
|
|
6/4/01
|
InterMune Announces Filing of Registration Statement For Public Offering of Common Stock
|
|
5/18/01
|
InterMune Honored by National Organization for Rare Disorders (NORD
|
|
5/18/01
|
Intermune to Present at UBS Warburg Global Specialty Pharmaceutical Conference
|
|
5/11/01
|
InterMune and MoliChem Enter Into Pulmonary Drug Development Collaboration
|
|
4/25/01
|
InterMune Announces First Quarter 2001 Financial Results and Conference Call
|
|
4/5/01
|
InterMune Completes Enrollment in Phase II Trial for Fungal Infections And Initiates Clinical Programs in Japan
|
|
3/26/01
|
InterMune Announces Webcast of Presentation at Banc of America Securities Healthcare Conference
|
|
3/26/01
|
InterMune and Boehringer Ingelheim Announce Formation of International Strategic Partnership
|
|
3/25/01
|
InterMune Announces Conference Call to Discuss International Strategic Partnership
|
|
3/23/01
|
Jay P. Shepard to Join InterMune Board of Directors
|
|
2/28/01
|
InterMune Initiates Phase II Trial of ACTIMMUNE(R) in the Treatment Of Cystic Fibrosis
|
|
2/27/01
|
InterMune Presentation to Lehman Brothers Global Healthcare Conference Available by Conference Call
|
|
2/15/01
|
InterMune Announces Fourth Quarter 2000 Financial Results and Conference Call
|
|
1/30/01
|
InterMune Expands U.S. Marketing and Sales Efforts
|
|
1/23/01
|
InterMune Announces Hiring of James Pennington, M.D. as Executive Vice President of Medical and Scientific Affairs
|
|
1/10/01
|
InterMune Acquires Amphotec(R) From ALZA
|
|
1/9/01
|
InterMune to Present at J.P. Morgan H&Q Healthcare Conference
|
|
1/3/01
|
InterMune Initiates Phase II Trial of Actimmune(R) in the Treatment of Atypical Mycobacterial Infections
|
|
1/3/01
|
InterMune Files New Drug Submission for Actimmune(R) in Canada
|
|
11/28/00
|
Protein Design Labs and InterMune Announce Antibody Humanization Agreement
|
|
11/16/00
|
Connetics Generates $42.2 Million Through the Sale of Intermune Shares
|
|
11/7/00
|
InterMune to Present at Prudential Vector Healthcare Conference
|
|
11/1/00
|
InterMune Announces Meeting to Discuss Clinical Advances in Idiopathic Pulmonary Fibrosis
|
|
10/23/00
|
InterMune Reports Third Quarter 2000 Financial Results
|
|
10/3/00
|
InterMune Initiates Phase III Trial of ACTIMMUNE in the Treatment of Idiopathic Pulmonary Fibrosis
|
|
9/29/00
|
InterMune Announces Publication of American Thoracic Society Monograph On the Management of Idiopathic Pulmonary Fibrosis
|
|
9/26/00
|
InterMune Announces Plans to Initiate Clinical Programs for ACTIMMUNE in Ovarian Cancer
|
|
9/18/00
|
ICAAC Abstract Reports Therapy With Antibody To PcrV Effective Against Pseudomonas Aeruginosa Pneumonia
|
|
8/17/00
|
InterMune Announces $76 Million Private Placement of Common Stock
|
|
8/3/00
|
InterMune Acquires Rights to Commercialize ACTIMMUNE In Japan for Infectious Diseases and Chronic Granulomatous Disease and Osteopetrosis
|
|
8/1/00
|
InterMune Enrolls First Patient in Phase III Trial in Multidrug-Resistant Tuberculosis
|
|
7/25/00
|
InterMune Reports Second Quarter 2000 Financial Results; Sales of ACTIMMUNE Increase by 178%
|
|
6/28/00
|
InterMune Acquires Rights to ACTIMMUNE Revenue
|
|
6/26/00
|
InterMune Acquires Rights to ACTIMMUNE(R) in Canada
|
|
6/8/00
|
InterMune Announces Senior Management Hires
|
|
5/3/00
|
InterMune Reports First Quarter 2000 Financial Results; Sales of ACTIMMUNE® Increase by 70%
|
|
4/13/00
|
Intermune Announces Results Presented At American Thoracic Society Medical Symposium
|
|
3/31/00
|
InterMune Announces Recent Executive Appointments
|
|
3/28/00
|
Researcher Comments on Letter to Editor Concerning Phase II Trial of Interferon Gamma-1B
|
|
3/6/00
|
InterMune Pharmaceuticals Elects Wayne T. Hockmeyer to Board of Directors
|
|
2/11/00
|
FDA Approval of ACTIMMUNE® Provides Hope for Children with Fatal Disease
|
|
2/7/00
|
Intermune Announces the Hiring of Christine W. Czarniecki as Vice-President, Regulatory Affairs
|
|
2/2/00
|
InterMune Initiates Phase II Trial Evaluating ACTIMMUNE® in the Treatment of Cryptococcal Meningitis
|
|
1/10/00
|
InterMune Completes $27 Million Private Financing
|
|
11/23/99
|
InterMune Announces the Hiring of Peter Van Vlasselaer as Senior Vice President, Technical Operations
|
|
11/11/99
|
InterMune Announces the Hiring of Timothy P. Lynch as Chief Financial Officer
|
|
11/5/99
|
InterMune Announces that a Controlled Clinical Study Supports the Use of Interferon Gamma-1b as a Treatment for Idiopathic Pulmonary Fibrosis
|
|
8/24/99
|
InterMune Pharmaceuticals Announces Filing of BLA for ACTIMMUNE® for the Treatment of Osteopetrosis
|
|
8/23/99
|
InterMune Pharmaceuticals Announces Completion of Series A Preferred Stock Financing
|
|
8/5/99
|
InterMune Pharmaceuticals Announces Nick Simon Elected to Board of Directors
|
|
4/30/99
|
InterMune Pharmaceuticals Completes Spin-Off from Parent and $6 Million in Private Placement Funding
|
